A synopsis on the role of tyrosine hydroxylase in Parkinson's disease

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 4, 2012, Pages 395-409

  Tabrez, Shams ^a   Jabir, Nasimudeen R ^a   Shakil, Shazi ^a   Greig, Nigel H ^b   Alam, Qamre ^a   Abuzenadah, Adel M ^a   Damanhouri, Ghazi A ^a   Kamal, Mohammad A ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

Dopamine; L DOPA; Neuroprotection; Neurotrophic factors; Parkinson disease; Tyrosine hydroxylase; synuclein

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; ALPHA SYNUCLEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; DOPAMINE; FERROUS ION; GLUTAMATE DECARBOXYLASE; HEPTACHLOR; NEURTURIN; PARAQUAT; PARKIN; PARVOVIRUS VECTOR; PYRIDOXAL 5 PHOSPHATE; ROTENONE; TETRAHYDROFOLIC ACID; TYROSINE 3 MONOOXYGENASE; UBIQUITIN THIOLESTERASE;

AMINO TERMINAL SEQUENCE; ARTICLE; BRAIN MITOCHONDRION; CHROMOSOME 11P; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; ENVIRONMENTAL FACTOR; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME BINDING; ENZYME LOCALIZATION; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; GENE MUTATION; GENE THERAPY; HOMEOSTASIS; HUMAN; MOLECULAR GENETICS; NEUROBLASTOMA; NEUROPATHOLOGY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SINGLE NUCLEOTIDE POLYMORPHISM; STEM CELL TRANSPLANTATION; STRUCTURAL HOMOLOGY; SUBTHALAMIC NUCLEUS;

EID: 84862563459     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152712800792785     Document Type: Article

References (251)

1. Kawajiri, S.; Saiki, S; Sato, S.; Hattori, N. Genetic mutations and functions of PINK1. Trends Pharmacol. Sci., 2011, 32(10), 573-580.
2. Bralten, J.; Aria, V.A.; Makkinje, R.; Veltman, J.A.; Brunner, H.G.; Fernández, G.; Rijpkema, M.; Franke, B. Association of the Alzheimer's gene SORL1 with hippocampal volume in young, healthy adults. Am. J. Psychiatry, 2011, 168(10), 1083-1189.
3. Litteljohn, D.; Mangano, E.; Clarke, M.; Bobyn, J.; Moloney, K.; Hayley, S. Inflammatory mechanisms of neurodegeneration in toxin-based models of Parkinson's disease. Parkinsons Dis., 2011, 2011, 713517.
4. Ruiz, P.J.; Catalán, M.J.; Carril, J.M.; Initial motor symptoms of Parkinson disease. Neurologist, 2011, 17, 18-20.
5. Stacy, M.A.; Murck, H.; Kroenke, K. Responsiveness of motor and nonmotor symptoms of Parkinson disease to dopaminergic therapy. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34(1), 57-61.
6. Hwang, D.Y.; Ardayfio, P.; Kang, U.J.; Semina, E.V.; Kim, K.S. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res., 2003, 114(2), 123-131.
7. Blanchard-Fillion, B.; Souza, J.M.; Friel, T.; Jiang, G.C; Vrana, K.; Sharov, V.; Barrón, L.; Schoneich, C.; Quijano, C.; Alvarez, B.; Radi, R.; Przedborski, S.; Fernando, G.S.; Horwitz, J.; Ischiropoulos, H. Nitration and inactivation of tyrosine hydroxylase by peroxynitrite. J. Biol. Chem., 2001, 276(49), 46017-46023.
8. Nagatsu, T. Change of tyrosine hydroxylase in the parkinsonian brain and in the brain of MPTP-treated mice as revealed by homospecific activity. Neurochem. Res., 1990, 15(4), 425-429.
9. Masalha, R.; Kordysh, E.; Alpert, G.; Hallak, M.; Morad, M.; Mahajnah, M.; Farkas, P.; Herishanu, Y. The prevalence of Parkinson's disease in an Arab population, Wadi Ara, Israel. Isr. Med. Assoc. J., 2010, 12(1), 32-35.
10. Wright Willis, A.; Evanoff, B.A.; Lian, M.; Criswell, S.R.; Racette, B.A. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology, 2010, 34(3), 143-151.
11. Muangpaisan, W.; Mathews, A.; Hori, H.; Seidel, D.A. Systematic review of the worldwide prevalence and incidence of Parkinson's disease. J. Med. Assoc. Thai., 2011, 94(6), 749-755.
12. Sha, D.; Chin, L.S.; Li, L. Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling. Hum. Mol. Genet., 2010, 19(2), 352-363.
13. Adams, J.D., Jr.; Chang, M.L.; Klaidman, L. Parkinson's diseaseredox mechanisms. Curr. Med. Chem., 2001, 8(7), 809-814.
14. Haavik, J., Toska, K. Tyrosine hydroxylase and parkinson's disease. Mol. Neurobiol., 1998, 16(3), 285-309.
15. Flatmark, T.; Stevens, R.C. Structural insight into the aromatic amino acid hydroxylases and their disease-related mutant forms. Chem. Rev., 1999, 99, 2137-2160.
16. Fitzpatrick, P.F. The aromatic amino acid hydroxylases. Adv. Enzymol. Relat. Areas Mol. Biol., 2000, 74, 235-294.
17. Flatmark, T.; Almas, B.; Ziegler, M.G. Catecholamine metabolism: an update on key biosynthetic enzymes and vesicular monoamine transporters. Ann. NY Acad. Sci., 2002, 971, 69-75.
18. Fitzpatrick, P.F. Allosteric regulation of phenylalanine hydroxylase. Arch. Biochem. Biophys., 2011, 519(2), 194-201.
19. Descarries, L.; Bérubé-Carrière, N.; Riad, M.; Bo, G.D.; Mendez, J.A.; Trudeau, L.E. Glutamate in dopamine neurons: synaptic versus diffuse transmission. Brain Res. Rev., 2008, 58(2), 290-302.
20. Tsudzuki, T.; Tsujita, M. Isoosmotic isolation of rat brain synaptic vesicles, some of which contain tyrosine hydroxylase. J. Biochem., 2004, 136, 239-243.
21. Cartier, E.A.; Parra, L.A.; Baust, T.B.; Quiroz, M.; Salazar, G.; Faundez, V., Egana, L.; Torres, G.E. A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. J. Biol. Chem., 2010, 285, 1957-1966.
22. Haycock, J. W.; Wakade, A.R. Activation and multiple-site phosphorylation of tyrosine hydroxylase in perfused rat adrenal glands. J. Neurochem., 1992, 58, 57-64.
23. Tierney, A.J.; Kim, T.; Abrams, R. Dopamine in crayfish and other crustaceans: distribution in the central nervous system and physiological functions. Microsc. Res. Tech., 2003, 60, 325-335.
24. Sanyal, S.; Wintle, R.F.; Kindt, K.S., Nuttley, W.M.; Arvan, R.; Fitzmaurice, P.; Bigras, E.; Merz, D.C.; Hebert, T.E.; Van Der Kooy, D.; Schafer, W.R.; Culotti, J.G.; Van Tol, H.H. Dopamine modulates the plasticity of mechanosensory responses in Caenorhabditis elegans. Eur. Mol. Biol. Organ J., 2004, 23(2), 473-482.
25. Kindt, K.S.; Quast, K.B.; Giles, A.C.; De, S.; Hendrey, D.; Nicastro, I.; Rankin, C.H.; Schafer, W.R. Dopamine mediates context-dependent modulation of sensory plasticity in C. elegans. Neuron, 2007, 55, 662-676.
26. Napolitano, A.; Manini, P.; d'Ischia, M. Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr. Med. Chem., 2011, 18, 1832-1845.
27. Sulzer, D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci., 2007, 30, 244-250.
28. Narendra, D.; Tanaka, A.; Suen, D.F.; Youle, R.J. Parkin-induced mitophagy in the pathogenesis of Parkinson diseas. J. Cell Biol., 2008, 183, 795-803.
29. Rabinovic, A.D.; Lewis, D.A.; Hastings, T.G. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. Neuroscience, 2000, 101, 67-76.
30. Staal, R.G.; Mosharov, E.V.; Sulzer, D. Dopamine neurons release transmitter via a flickering fusion pore. Nat. Neurosci., 2004, 7, 341-346.
31. Caudle, W.M.; Richardson, J.R.; Wang, M.Z.; Taylor, T.N.; Guillot, T.S.; McCormack, A.L.; Colebrooke, R.E.; Di Monte, D.A.; Emson, P.C.; Miller, G.W. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci., 2007, 27, 8138-8148.
32. Gasser, T. Mendelian forms of Parkinson's disease. Biochem. Biophys. Acta, 2009, 1792, 587-596.
33. Martin, H.L.; Teismann, P. Piccini, P.; Burn, D. J.; Ceravolo, R.; Maraganore, D.; Brooks, D. J. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann. Neurol., 2009, 45, 577-582.
34. Siltberg-Liberles, J.; Steen, I.H.; Svebak, R.M.; Martinez, A. The phylogeny of the aromatic amino acid hydroxylases revisited by characterizing phenylalanine hydroxylase from Dictyostelium discoideum. Gene, 2008, 427, 86-92.
35. Dunkley, P.R.; Bobrovskaya, L.; Graham, M.E.; von Nagy-Felsobuki, E.I.; Dickson, P.W. Tyrosine hydroxylase phosphorylation:regulation and consequences. J. Neurochem., 2004, 91, 1025-1043.
36. Calvo Ana, C. Function and regulation of phenylalanine and tyrosine hydroxylases from human and Caenorhabditis elegans. With focus in evolutionary aspects and development of new therapies. PhD Thesis, The University of Bergen, June 2010.
37. Goodwill, K.E.; Sabatier, C.; Marks, C.; Raag, R.; Fitzpatrick, P.F.; Stevens, R.C. Crystal structure of tyrosine hydroxylase at 2.3 Ao and its implications for inherited neurodegenerative diseases. Nat. Struct. Biol., 1997, 4, 578-585.
38. Haycock, J.W.; Haycock, D.A. Tyrosine hydroxylase in rat brain dopaminergic nerve terminals: Multiple-site phosphorylation in vivo and in synaptosomes. J. Biol. Chem., 1991, 266, 5650-5657.
39. Haycock, J.W.; Lew, J.Y.; Garcia-Espana, A.; Lee KY, Harada, K.; Meller, E.; Goldstein, M. Role of Serine-19 phosphorylation in regulating tyrosine hydroxylase studied with site- and phosphospecific antibodies and site-directed mutagenesis. J. Neurochem., 1998, 71(4), 1670-1675.
40. Salvatore, M.F.; Waymire, J.C.; Haycock, J.W. Depolarizationstimulated catecholamine biosynthesis: involvement of protein kinases and tyrosine hydroxylase phosphorylation sites in situ. J. Neurochem., 2001, 79(2), 349-360.
41. Conner, J.R.; Wang, X.S.; Allen, R.P.; Beard, J.L.; Wiesinger, J.A.; Felt, B.T.; Earley, C.J. Altered dopaminergic profile in the putamen and substantia nigra in restless leg syndrome. Brain, 2009, 132(9), 2403-2412.
42. Salvatore, M.F.; Fisher, B.; Surgener, S.P.; Gerhardt, G.A.; Rouault, T. Neurochemical investigations of dopamine neuronal systems in iron-regulatory protein 2(IRP-2) knockout mice. Brain Res. Mol. Brain. Res., 2005, 139(2), 341-347.
43. Nagatsu, T. The human tyrosine hydroxylase gene. Cell. Mol. Neurobiol., 1989, 9(3), 313-321.
44. Dumas, S.; Le Hir, H.; Bodeau-Pean, S.; Hirsch, E.; Thermes, C.; Mallet, J. New species of human tyrosine hydroxylase mRNA are produced in variable amounts in adrenal medulla and are overexpressed in progressive supranuclear palsy. J. Neurochem., 1996, 67, 19-25.
45. Ohye, T.; Ichinose, H.; Yoshizawa, T.; Kanazawa, I.; Nagatsu, T. A new splicing variant for human tyrosine hydroxylase in the adrenal medulla. Neurosci. Lett., 2001, 312, 157-160.
46. Roma, J.; Saus, E.; Cuadros, M.; Reventos, J.; Sanchez de Toledo, J.; Gallego, S. Characterisation of novel splicing variants of the tyrosine hydroxylase C-terminal domain in human neuroblastic tumours. Biol. Chem., 2007, 388, 419-426.
47. Kaufman, S. Tyrosine hydroxylase. Adv. Enzymol. Relat. Areas Mol. Biol., 1995, 70, 103-220.
48. Daubner, S.C.; Le, T.; Wang, S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys., 2011, 508(1), 1-12.
49. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. Physiol. Rev., 2011, 91(4), 1161-1218.
50. Bernheimer, H.; Birkmayer, W.; Hornykiewicz, O.; Jellinger, K.; Seitelberger, F. Brain DA and the syndromes of Parkinson and Huntington: clinical, morphological, and neurochemical correlations. J. Neurol. Sci., 1973, 20, 415-455.
51. Hornykiewicz, O.; Kish, S.J. Biochemical pathophysiology of Parkinson's disease. Adv. Neurol., 1986, 45, 19-34.
52. Martin, F.L.; Williamson, S.J.; Paleologou, K.E.; Allsop, D.; El Agnaf, O.M. Alpha-synuclein and the pathogenesis of Parkinson's disease. Protein Pept. Lett., 2004, 11(3), 229-237.
53. Galvin, J.E.; Lee, V.M.; Trojanowski, J.Q. Synucleinopathies: clinical and pathological implications. Arch. Neurol., 2001, 58, 186-190.
54. Perez, R.G.; Waymire, J.C.; Lin, E.; Liu, J.J.; Guo, F.; Zigmond, M.J.; A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci., 2002, 22(8), 3090-3099.
55. Takeda, A.; Hashimoto, M.; Mallory, M.; Sundsumo, M.; Hansen, L.; Sisk, A.; Masliah, E. Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alphasynuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab. Invest., 1998, 78, 1169-1177.
56. Jenner, P. Olanow, C.W. Oxidative stress and the pathogenesis of Parkinson's disease. Neurology, 1996, 47, 161-170.
57. Markopoulou, K.; Wszolek, ZK.; Pfeiffer, R.F.; Chase, B.A. Reduced expression of the G209A alpha-synuclein allele in familial Parkinsonism. Ann. Neurol., 1999, 46, 374-381.
58. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Synuclein in Lewy bodies. Nature, 1997, 388, 839-840.
59. Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goedert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA, 1998, 95, 6469-6473.
60. Maroteaux, L.; Campanelli, J.T.; Scheller, R.H. Synuclein: a neuronspecific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci., 1988, 8, 2804-2815.
61. Xiangmin, M.; Peng, R.; Tehranian, P.D.; Leonidas, S.; Ruth, G. α-Synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J. Cell Sci., 2005, 118, 3523-3530.
62. George, R.J.; Haycock, J.W.; Johnston, J.P.; Craviso, G.L; Waymire, J.C. In vitro phosphorylation of bovine adrenal chromaffin cell tyrosine hydroxylase by endogenous protein kinases. J. Neurochem., 1989, 52(1), 274-284.
63. Kim, S.S.; Moon, K.R.; Choi, H.J. Interference of alpha-synuclein with cAMP/PKA-dependent CREB signaling for tyrosine hydroxylase gene expression in SK-N-BE(2)C cells. Arch. Pharm. Res., 2011, 34(5), 837-845.
64. Perez, R.G.; Hastings, T.G. Could a loss of alpha-synuclein function put dopaminergic neurons at risk? J. Neurochem., 2004, 89, 1318-1324.
65. Mori, F.; Nishie, M.; Kakita, A.; Yoshimoto, M.; Takahashi, H.; Wakabayashi, K. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra. J. Neuropathol. Exp. Neurol., 2006, 65(8), 808-815.
66. Gao, N.; Li, Y.H.; Li, X.; Yu, S.; Fu, G.L.; Chen, B. Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene. Neurosci. Bull., 2007, 23(1), 53-57.
67. Liu, D.; Jin, L.; Wang, H.; Zhao, H.; Zhao, C.; Duan, C.; Lu, L.; Wu, B.; Yu, S., Chan, P.; Li, Y.; Yang, H. Silencing alphasynuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells. Neurochem. Res., 2008, 33(7), 1401-1409.
68. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein J.; Boyer, R.; Stenroos, E.S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnson, W.G.; Lazzarini, A.M.; Duvoisin, R.C.; Di Iorio, G.; Golbe, L.I.; Nussbaum, R.L. Mutation in the synuclein gene identified in families with Parkinson's disease. Science, 1997, 276, 2045-2047.
69. Kruger, R.; Kuhn, W.; Muller, T.; Woitalla, D.; Graeber, M.; Kosel, S.; Przuntek, H.; Epplen, J.T.; Schols, L.; Riess, O.Ala30Pro mutation in the gene encoding synuclein in Parkinson's disease. Nat. Genet., 1998, 18, 106-108.
70. Neystat, M.; Lynch, T.; Przedborski, S.; Kholodilov, N.; Rzhetskaya, M.; Burke, R. Synuclein expression in substantia nigra and cortex in Parkinson's disease. Mov. Disord., 1999, 14, 417-422.
71. Masliah, E.; Rockenstein, E.; Veinbergs, I.; Mallory, M.; Hashimoto, M.; Takeda, A.; Sagara, Y.; Sisk, A.; Mucke, L. Dopaminergic loss and inclusion body formation in alphasynuclein mice: implications for neurodegenerative disorders. Science, 2000, 287, 1265-1269.
72. Conway, K.A.; Lee, S.J.; Rochet, J.C.; Ding, T.T.; Harper, J.D.; Williamson, R.E.; Lansbury, P.T. Jr. Accelerated oligomerization by Parkinson's disease linked alpha-synuclein mutants. Acad. Sci., 2000, 920, 42-45.
73. Kim, T.D.; Paik, S.R.; Yang, C.H.; Kim, J. Structural changes in alphasynuclein affect its chaperone-like activity in vitro. Prot. Sci., 2000, 9, 2489-2496.
74. Souza, J.M.; Giasson, B.I.; Lee, V.M.Y.; Ischiropoulos, H. Chaperonelike activity of synucleins. FEBS Lett., 2000, 474, 116-119.
75. Ostrerova, N.; Petrucelli, L.; Farrer, M.; Mehta, N.; Choi, P.; Hardy, J.; Wolozin, B. Synuclein shares physical and functional homology with 14-3-3. J. Neurosci., 1999, 19, 5782-5791.
76. Ichimura, T.; Isobe, T.; Okuyama, T.; Takahashi, N.; Araki, K.; Kuwano, R.; Takahashi, Y. Molecular cloning of cDNA coding for brainspecific 14-3-3 protein, a protein kinase-dependent activator of tyrosine and tryptophan hydroxylases. Proc. Natl. Acad. Sci. USA, 1998, 85, 7084-7088.
77. Muslin, A.J.; Xing, H. 14-3-3 proteins: regulation of subcellular localization by molecular interference. Cell Signal., 2000, 12, 703-709.
78. Kumer, S.C.; Vrana, K.E. Intricate regulation of tyrosine hydroxylase activity and gene expression. J. Neurochem., 1996, 67(2), 443-462.
79. Zhang, L.; Wang, H.; Liu, D.; Liddington, R.; Fu, H. Raf-1 kinase and exoenzyme S interact with 14-3-3 zeta through a common site involving lysine 49. J. Biol. Chem., 1997, 272, 13717-13724.
80. Kleppe, R.; Toska, K.; Haavik, J. Interaction of phosphorylated tyrosine hydroxylase with 14-3-3 proteins: evidence for a phosphoserine 40-dependent association. J. Neurochem., 2001, 77, 1097-1107.
81. Itagaki, C.; Isobe, T.; Taoka, M.; Natsume, T.; Nomura, N.; Horigome, T.; Omata, S.; Ichinose, H.; Nagatsu, T.; Greene, L.A.; Ichimura, T. Stimulus coupled interaction of tyrosine hydroxylase with 14-3-3 proteins. Biochemistry, 1999, 38, 15673-15680.
82. Butterfield, P.G.; Valanis, B.G.; Spencer, P.S.; Lindeman, C.A.; Nutt, J.G. Environmental antecedents of young-onset Parkinson's disease. Neurology, 1993, 43(6), 1150-1158.
83. Gorell, J. M.; Johnson, C.C.; Rybicki, B.A.; Peterson, E.L.; Kortsha, G.X.; Brown, G.G.; Richardson, R.J. Occupational exposures to metals as risk factors for Parkinson's disease. Neurology, 1997, 48(3), 650-658.
84. Menegon, A.; Board, P.G.; Blackburn, A.C.; Mellick, G.D.; Fracp, D.G.L.C. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet, 1998, 352(9137), 1344-1346.
85. Ho, S.C.; Woo, J.; Lee, C.M. Epidemiologic study of Parkinson's disease in Hong Kong. Neurology, 1989, 39(10), 1314-1318.
86. Cranmer, J.M. Parkinson's disease, environment and genes. Neurotoxicology, 2001, 22(6), 829-832.
87. Di Monte, D.A.; Lavasani, M.; Manning-Bog, A.B. Environmental factors in Parkinson's disease. Neurotoxicology, 2002, 23(4-5), 487-502.
88. Langston, J.W. Parkinson's disease: current and future challenges. Neurotoxicology, 2002, 23(4-5), 443-450.
89. Betarbet, R.; Sherer, T. B.; MacKenzie, G. Garcia-Osuna, M.; Panov, A.V.; Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci., 2000, 3(12), 1301-1306.
90. Costello, S.; Cockburn, M.; Bronstein, J.; Zhang, X., Ritz, B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am. J. Epidemiol., 2009, 169(8), 919-926.
91. Firestone, J.A.; Smith-Weller, T.; Franklin, G.; Swanson, P.; Longstreth, W.T. Jr.; Checkoway, H. Pesticides and risk of Parkinson disease: a population-based case-control study. Arch. Neurol. 2005, 62(1), 91-95.
92. Thiruchelvam, M.; Richfield, E. K.; Goodman, B.M.; Baggs, R.B., Dory-Slechta, D.A. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology, 2002, 23(4-5), 621-633.
93. Kirby, M.L.; Barlow, R.L.; Bloomquist, J.R. Neurotoxicity of the organochlorine insecticide heptachlor to murine striatal dopaminergic pathways. Toxicol. Sci., 2001, 61(1), 100-106.
94. Thrash, B.; Uthayathas, S.; Karuppagounder, S.S.; Suppiramaniam, V.; Dhanasekaran, M. Paraquat and maneb induced neurotoxicity. Proc. West Pharmacol. Soc., 2007, 50, 31-42.
95. Li, X.; Yin, J.; Cheng, C.M.; Sun, J.L.; Li, Z.; Wu, Y.L. Paraquat induces selective dopaminergic nigrostriatal degeneration in aging C57BL/6 mice. Chin. Med. J. (Engl)., 2005, 118(16), 1357-1361.
96. Brooks, A.I.; Chadwick, C.A.; Gelbard, H.A.; Cory-Slechta, D.A.; Federoff, H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res., 1999, 823(1-2), 1-10.
97. Gong-Ping, L.; Qiang, M.A.; Nian, S. Tyrosine hydroxylase as a target for deltamethrin in the nigrostriatal dopaminergic pathway1. Biomed. Env. Sci., 2006, 19, 27-34.
98. Bonifati, V.; Rizzu, P.; van Baren, M.J.; Schaap, O.; Breedveld, G.J.; Krieger, E.; Dekker, M.C.; Squitieri, F.; Ibanez, P.; Joosse, M.; van Dongen, J.W.; Vanacore, N.; van Swieten, J.C.; Brice, A.; Meco, G.; van Duijn, C.M.; Oostra, B.A.; Heutink, P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science, 2003, 299, 256-259.
99. Mouradian, M.M. Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology, 2002, 58, 179-185.
100. Maimone, D.; Dominici, R.; Grimaldi, L.M. Pharmacogenomics of neurodegenerative diseases. Eur. J. Pharmacol., 2001, 413, 11-29.
101. Zettergren, A. Genetics of parkinson's disease with focus on genes of relevance for inflammation and dopamine neuron development. 2010. Ph.D Thesis, University of Gothenburg, Sweden. ISBN 978-91-628-8022-4.
102. Tan, E.K.; Khajavi, M.; Thornby, J.I.; Nagamitsu, S.; Jankovic, J.; Ashizawa, T. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology, 2000, 55, 533-538.
103. Lee, C.G.L.; Tang, K.; Cheung, Y.B.; Wong, L.P.; Tan, C.; Shen, H.; Zhao, Y.; Pavanni, R.; Lee, E.J.D.; Wong, M.C.; Chong, S.S.; Tan, E.K. MDR1, the blood-brain barrier transporter, is associated with Parkinson's disease in ethnic Chinese. J. Med. Genet., 2004, 41, e60. http://jmg.bmj.com/content/41/5/e60.full-aff-6
104. Jingzhong, Z.; Hui, Y.; Deyi, D.; Chunli, D.; Chunli, Z.; Xiaohong, S.; Qunyuan, X. Long-term therapeutic effects on parkinsonian rats of intrastriatal co-grafts with genetically engineered fibroblasts expressing tyrosine hydroxylase and glial cell line-derivedneurotrophic factor. Int. J. Neurosci., 2005, 115, 769-779.
105. Dunnett, S.B.; Björklund, A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature, 1999, 399(6738), A32-A39.
106. Calon, F.; Grondin, R.; Morissette, M.; Goulet, M.; Blanchet, P.J.; Di Paolo, T.; Bedard, P.J. Molecular basis of levodopa-induced dyskinesias. Ann. Neurol., 2000, 47(4), 70-78.
107. Schapira, A.H.; Bezard, E.; Brotchie, J.; Calon, F.; Collingridge, G.L.; Ferger, B.; Hengerer, B.; Hirsch, E.; Jenner, P.; Le Novère, N.; Obeso, J.A.; Schwarzschild, M.A.; Spampinato, U.; Davidai, G. Novel pharmacological targets for the treatment of Parkinson's disease. Nat. Rev. Drug. Discov., 2006, 5(10), 845-854.
108. Marsden, C.D. Problems with long-term levodopa therapy for Parkinson's disease. Clin. Neuropharmacol., 1994, 17(2), S32-S44
109. Ahlskog, J.E; Muenter, M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord., 2001, 16(3), 448-458.
110. Burton, E.A.; Glorioso, J.C.; Fink, D.J. Gene therapy progress and prospects: Parkinson's disease. Gene Ther., 2003, 10, 1721-1727.
111. Manuchair, E.; Shashi, K.; Srinivasan Mayur, D.B. Oxidative stress and antioxidant therapy in parkinson's disease. Prog. Neurobiol., 1996; 48, 1-19.
112. Gupta, A.; Dawson, T.M.; The role of stem cells in Parkinson's disease. Neurosurg. Clin. N. Am., 2007, 18(1), 129-142.
113. Rangasamy, S.B.; Soderstrom, K.; Bakay, R.A.; Kordower, J.H. Neurotrophic factor therapy for Parkinson's disease. Prog. BrainRes., 2010, 184, 237-264.
114. Wijeyekoon, R.; Barker, R.A. Cell replacement therapy for Parkinson's disease. Biochim. Biophys. Acta, 2009, 1792(7), 688-702.
115. Cooper, J.R.; Bloom, F.E.; Roth, R.H. The Biochemical basis of Neuropharmacology, Oxford University Press, New York, 1991, pp. 285-337.
116. Lewitt, P.A.; Rezai, A.R.; Leehey, M.A.; Ojemann, S.G.; Flaherty, A.W.; Eskandar, E.N.; Kostyk, S.K.; Thomas, K.; Sarkar, A.; Siddiqui, M.S.; Tatter, S.B.; Schwalb, J.M.; Poston, K.L.; Henderson, J.M.; Kurlan, R.M.; Richard, I.H.; Van Meter, L.; Sapan, C.V.; During, M.J.; Kaplitt, M.G.; Feigin, A. AAV2-GAD gene therapy for advanced Parkinson's disease: a doubleblind, sham-surgery controlled, randomised trial. Lancet Neurol., 2011, 10(4), 309-319.
117. Marks, W.J.; Bartus, R.T.; Siffert, J.; Davis, C.S.; Lozano, A.; Boulis, N.; Vitek, J.; Stacy, M.; Turner, D.; Verhagen, L.; Bakay, R.; Watts, R.; Guthrie, B.; Jankovic, J.; Simpson, R.; Tagliati, M.; Alterman, R.; Stern, M.; Baltuch, G.; Starr, P.A.; Larson, P.S.; Ostrem, J.L.; Nutt, J.; Kieburtz, K.; Kordower, J.H.; Olanow, C.W. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol., 2010, 9(12), 1164-1172.
118. Rodnitzky, R.L. Upcoming treatments in Parkinson's disease, including gene therapy. Parkinsonism. Relat. Disord., 2012, 18(1), 37-40.
119. Muramatsu, S.; Fujimoto, K.; Kato, S.; Mizukami, H.; Asari, S.; Ikeguchi, K.; Kawakami, T.; Urabe, M.; Kume, A.; Sato, T.; Watanabe, E.; Ozawa, K.; Nakano, I. A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease. Mol. Ther., 2010, 18, 1731-1735.
120. Zheng, B.; Liao, Z.; Locascio, J.J.; Lesniak, K.A.; Roderick, S.S.; Watt, M.L.; Eklund, A.C.; Zhang-James, Y.; Kim, P.D.; Hauser, M.A.; Grünblatt, E.; Moran, L.B.; Mandel, S.A.; Riederer, P.; Miller, R.M.; Federoff, H.J.; Wüllner, U.; Papapetropoulos, S.; Youdim, M.B.; Cantuti-Castelvetri, I.; Young, A.B.; Vance, J.M.; Davis, R.L.; Hedreen, J.C.; Adler, C.H.; Beach, T.G.; Graeber, M.B.; Middleton, F.A.; Rochet, J.C.; Scherzer, C.R.; Global, P.D.; Gene Expression (GPEX) Consortium. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson's disease. Sci. Transl. Med., 2010, 2(52), 52-73.
121. Jiao, S.; Cheng, L.; Wolff, J.; Yang, N.S. Particle bombardmentmediated gene transfer and expression in rat brain tissues. Biotechnology, 1993, 11, 497-502.
122. Cheng, L.; Ziegelhoffer, P.; Yang, N.S. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment. Proc. Natl. Acad. Sci. USA, 1993,90, 4455-4459.
123. Roessler, B.; Davidson, B. Direct plasmid mediated transfection of adult murine brain cells in vivo using cationic liposomes. Neurosci. Lett., 1994, 167, 5-10.
124. Emborga, M.E.; Deglonb, N.; Leventhala, L.; Aebischerb, P.C.; Kordowera, J.H. Viral vector-mediated gene therapy for Parkinson's disease. Clin. Neurosci. Res., 2001, 1(6), 496-506.
125. Kaplitt, M.G.; Leone, P.; Samulski, R.J.; Xiao, X.; Pfaff, D.W.; O'Malley, K.L.; During, M.J. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet., 1994, 8, 148-154.
126. During, M.J.; Naegele, J.R.; Geller, A.I. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science, 1994, 266, 1399-1403.
127. Mandel, R.J.; Rendahl, K.G.; Spratt, S.K.; Snyder, R.O.; Cohen, L.K.; Leff, S.E. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J. Neurosci., 1998, 18, 4271-4284.
128. Fan, D.S.; Ogawa, M.; Fujimoto, K.I.; Ikeguchi, K.; Ogasawara, Y.; Urabe, M.; Nishizawa, M.; Nakano, I.; Yoshida, M.; Nagatsu, I.; Ichinose, H.; Nagatsu, T.; Kurtzman, G.J.; Ozawa, K. Behavioral recovery in 6- hydroxydopamine-lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic l-amino acid decarboxylase genes using two separate adenoassociated virus vectors. Hum. Gene Ther., 1998, 9, 2527-2535.
129. Shen, Y.; Muramatsu, S.I.; Ikeguchi, K.; Fujimoto, K.I.; Fan, D.S.; Ogawa, M.; Mizukami, H.; Urabe, M.; Kume, A.; Nagatsu, I.; Urano, F.; Suzuki, T.; Ichinose, H.; Nagatsu, T.; Monahan, J.; Nakano, I.; Ozawa, K. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-l-aminoacid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum. Gene Ther., 2000, 11, 1509-1519.
130. Fisher, L.J.; Jinnah, H.A.; Kale, L.C.; Gage, F.H. Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron, 1991, 6, 371-380.
131. Guerrero-Cazares, H.; Alatorre-Carranza, M.P.; Delgado-Rizo, V.; Duenas-Jimenez, J.M.; Mendoza-Magana, M.L.; Morales-Villagran, A.; Ramirez-Herrera, M.A.; Guerrero-Hernández, A.; Segovia, J.; Duenas-Jimenez, S.H. Dopamine release modifies intracellular calcium levels in tyrosine hydroxylase-transfected C6 cells. Brain Res. Bull., 2007, 74(1-3), 113-118.
132. Lundberg, C.; Horellou, P.; Bjorklund, A. Generation of DOPA producing astrocytes by retroviral transduction of the human tyrosine hydroxylase gene: in vitro characterization and in vivo effects in the rat Parkinson model. Exp. Neurol., 1996, 139, 39-53.
133. Zhang, S.; Zou, Z.; Jiang, X.; Xu, R.; Zhang, W.; Ke, Y. The therapeutic effects of tyrosine hydroxylase gene transfected hematopoetic stem cells in a rat model of Parkinson's disease. Cell Mol. Neurobiol., 2008, 28, 529-543.
134. Ishida, A.; Yasuzumi, F. Approach to ex vivo gene therapy in the treatment of Parkinson's disease. Brain Dev., 2000, 22, 143-147.
135. McCoy, M.K.; Ruhn, K.A.; Martinez, T.N.; McAlpine, F.E.; Tansey, M.G. Intranigral lentiviral delivery of dominant-negative TNF attenuates neurodegeneration and behavioral deficits in hemiparkinsonian rats. Mol. Ther., 2008, 16, 1572-1579.
136. Park, H.J.; Lee, P.H.; Bang, O.Y.; Ahn, Y.H. Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson's disease. J. Neurochem., 2008, 107, 141-151.
137. Chou, J.; Greig, N.H.; Reiner, D.; Hoffer, B.J.; Wang, Y. Enhanced survival of dopaminergic neuronal transplants in hemiparkinsonian rats by the p53 inactivator PFT-α. Cell Transplant., 2011, 20, 1351-1359.
138. Przedborski, S.; Jackson-Lewis, V.; Naini, A.B.; Jakowec, M.; Petzinger, G.; Miller, R.; Akram, M. The parkinsonian toxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine(MPTP): a technical review of its utility and safety. J. Neurochem., 2001, 76(5), 1265-1274.
139. Przedborski, S.; Jackson-Lewis, V. Mechanisms of MPTP toxicity. Mov. Disord., 1998, 13, 35-38.
140. Chung, Y.C.; Kim, S.R.; Park, J.Y.; Chung, E.S.; Park, K.W.; Won, S.Y.; Bok, E.; Jin, M.; Park, E.S.; Yoon, S.H.; Ko, H.W.; Kim, Y.S.; Jin, B.K. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting micriglial activation. Neuropharmacology, 2011, 60(6), 963-974.
141. Huh, S.H.; Chung, Y.C.; Piao, Y.; Jin, M.Y.; Son, H.J.; Yoon, N.S.; Hong, J.Y.; Pak, Y.K.; Kim, Y.S.; Hong, J.K.; Hwang, O.; Jin, B.K. Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. J. Immunol., 2011, 187(2), 960-969.
142. Chung, Y.C.; Kim, S.R.; Jin, B.K. Paroxetine Prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of parkinson's disease. J. Immunol., 2010, 185, 1230-1237.
143. Schapira, A.H. Evidence for mitochondrial dysfunction in Parkinson's disease - a critical appraisal. Movem. Disord., 1994, 9, 125-138.
144. Haas, R.H.; Nasirian, F.; Nakano, K.; Ward, D.; Pay, M.; Hill, R.; Shults, C.W. Low platelet mitochondrial complex I and complexII/III activity in early untreated Parkinson's disease. Ann. Neurol., 1995, 37, 714-722.
145. Martin, H.L.; Teismann, P. Glutathione-a review on its role and significance in Parkinson's disease. FASEB. J., 2009, 23(10), 3263-3272.
146. Banerjee, R.; Starkov, A.A.; Beal, M.F.; Thomas, B. Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim. Biophys. Acta, 2009, 1792, 651-663.
147. Hastings, T. G.; Zigmond, M.J. Loss of dopaminergic neurons in parkinsonism: possible role of reactive dopamine metabolites. J. Neural Transm., 1997, 49, 103-110.
148. Halliwell, B. Reactive oxygen species and the central nervous system. J. Neurochem., 1992, 59, 1609-1623.
149. Miyazaki, I.; Asanuma, M. Dopaminergic neuron-specific oxidative stress caused by dopamine itself. Acta. Med. Okayama, 2008, 62, 141-150.
150. Calabrese, E. J. Pharmacological enhancement of neuronal survival. Crit. Rev. Toxicol., 2008, 38, 349-389.
151. Otani, H. Reactive oxygen species as mediators of signal transduction in ischemic preconditioning. Antioxid. Redox. Signal., 2004, 6, 449-469.
152. Jia, Z.; Zhu, H.; Misra, B. R.; Misra, H.P. Dopamine as a potent inducer of cellular glutathione and NAD(P)H:quinine oxidoreductase 1 in PC12 neuronal cells: a potential adaptive mechanism for dopaminergic neuroprotection. Neurochem. Res., 2008, 33, 2197-2205.
153. Lazou, A.; Markou, T.; Zioga, M.; Vasara, E.; and Gaitanaki, C. Dopamine mimics the cardioprotective effect of ischemic preconditioning via activation of alpha1-adrenoceptors in the isolated rat heart. Physiol. Res., 2006, 55, 1-8.
154. Shih, A.Y.; Murphy, T.H. Dopamine activates Nrf2-regulated neuroprotective pathways in astrocytes and meningeal cells. J. Neurochem., 2007, 101, 109-119.
155. Franco, J.L.; Posser, T.; Gordon, S.L.; Bobrovskaya, L.; Schneider, J.J.; Farina, M.; Dafre, A.L.; Dickson, P.W.; Dunkley, P.R. Expression of tyrosine hydroxylase increases the resistance of human neuroblastoma cells to oxidative insults. Toxicol. Sci., 2010, 113(1), 150-157.
156. McCormack, A.L.; Atienza, J.G.; Langston, J.W.; Di Monte, D.A. Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience, 2006, 141, 929-937.
157. Olanow, C.W.; Obeso, J.A. Preventing levodopa-induced dyskinesias. Ann. Neurol., 2000, 47, 167-176.
158. Freed, C.R.; Breeze, R.E.; Rosenberg, N.L. Transplantation of human fetal dopamine cells for Parkinson's disease: results at 1 year. Arch. Neurol., 1990, 47, 505-512.
159. Freed, C.R.; Greene, P.E.; Breeze, R.E. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med., 2001, 344, 710-719.
160. Kimberley, A.; Buytaert-Hoefen, E.; Alvarez, Curt, R.F. Generation of Tyrosine Hydroxylase Positive Neurons from Human Embryonic Stem Cells after Coculture with Cellular Substrates and Exposure to GDNF. Stem Cells, 2004, 22, 669-674.
161. Bjorklund, L.M.; Sanchez-Pernaute, R.; Chung, S. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc. Natl. Acad. Sci. USA, 2002, 99, 2344-2349.
162. Deacon, T.; Dinsmore, J.; Costantini, L.C. Blastula-stage stem cells can differentiate into dopaminergic and serotonergic neurons after transplantation. Exp. Neurol., 1998, 149, 28-41.
163. Kawasaki, H.; Mizuseki, K.; Nishikawa, S. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron, 2000, 28, 31-40.
164. Kawasaki, H.; Suemori, H.; Mizuseki, K. Generation of dopaminergic neurons and pigmented epithelia from primate ES cells by stromal cell-derived inducing activity. Proc. Natl. Acad. Sci. USA, 2002, 99, 1580-1585.
165. Zou, Z.; Jiang, X.; Zhang, W.; Zhou, Y.; Ke, Y.; Zhang, S.; Xu, R. Efficacy of Tyrosine Hydroxylase gene modified neural stem cells derived from bone marrow on Parkinson's disease a rat model study. Brain Res., 2010, 1346, 279-286.
166. Kirik, D.; Georgievska, B.; Bjorklund, A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci., 2004, 7, 105-110.
167. Lang, A.E.; Gill, S.; Patel, N.K.; Lozano, A.; Nutt, J.G.; Penn, R.; Brooks, D.J.; Hotton, G.; Moro, E.; Heywood, P. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol., 2006, 59, 459-466.
168. Pascual, A.; Hidalgo F.M.; Gomez D.R.; Lopez B.J. GDNF and protection of adult central catecholaminergic neurons. J. Mol. Endocrinol., 2011, 46(3), R83-R92.
169. Ibanez, C.F. Message in a bottle: long-range retrograde signaling in the nervous system. Trend. Cell Biol., 2007, 17, 519-528.
170. Lin, L.F.; Doherty, D.H.; Lile, J.D.; Bektesh, S.; Collins, F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science, 1993, 260, 1130-1132.
171. Pascual, A.; Hidalgo-Figueroa, M.; Piruat, J.I.; Pintado, C.O.; Gomez-Diaz, R.; Lopez-Barneo, J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci., 2008, 11, 755-761.
172. Tomac, A.; Lindqvist, E.; Lin, L.F.; Ogren, S.O.; Young, D.; Hoffer, B.J.; Olson, L. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature, 1995, 373, 335-339.
173. Gill, S.S.; Patel, N.K.; Hotton, G.R.; O'Sullivan, K.; McCarter, R.; Bunnage, M.; Brooks, D.J; Svendsen, C.N.; Heywood, P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med., 2003, 9, 589-595.
174. Vastag, B. Biotechnology: crossing the barrier. Nature, 2010, 466, 916-918.
175. Chadi, G, Moller, A.; Rosen, L.; Janson, A.M.; Agnati, L.A.; Goldstein, M.; Ogren, S.O.; Pettersson, R.F.; Fuxe, K. Protective actions of human recombinant basic fibroblast growth factor on MPTP-lesioned nigrostriatal dopamine neurons after intraventricular infusion. Exp. Brain Res., 1993, 97(1), 145-158.
176. Duobles, T.; Lima, T.S.; Levy, B.F.; Chadi, G.S. 100 beta and fibroblast growth factor-2 are present in cultured Schwann cells and may exert paracrine actions on the peripheral nerve injury. Acta Cir. Braz., 2008, 23(6), 555-560.
177. Grothe, C.; Haastert, K.; Jungnickel, J. Physiological function and putative therapeutic impact of the FGF-2 system in peripheral nerve regeneration-lessons from in vivo studies in mice and rats. Brain Res. Rev., 2006, 51(2), 293-299.
178. Mattson, M.P. Glutamate and neurotrophic factors in neuronal plasticity and disease. Ann. NY Acad. Sci., 2008, 1144, 97-112.
179. Xu, G.; Xiong, Z.; Yong, Y.; Wang, Z.; Ke, Z.; Xia, Z.; Hu, Y. Catalpol attenuates MPTP induced neuronal degeneration of nigralstriatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum. Neuroscience, 2010, 167(1), 174-184.
180. Wang, Z.; Liu, Q.; Zhang, R.; Liu, S.; Xia, Z.; Hu, Y. Catalpol ameliorates beta amyloid-induced degeneration of cholinergic neurons by elevating brain-derived neurotrophic factors. Neuroscience, 2009, 163(4), 1363-1372.
181. Airavaara, M.; Harvey, B.K.; Voutilainen, M.H.; Shen, H.; Chou, J.; Lindholm, P.; Lindahl, M.; Tuominen, R.K.; Saarma, M.; Wang, Y.; Hoffer, B. CDNF protects the nigrostriatal DA system and promotes recovery after MPTP treatment in mice. Cell Transplant., 2011, Epub ahead of print.
182. Lindholm, P.; Voutilainen, M.H.; Laurén, J.; Peranen, J.; Leppanen, V.M.; Andressoo, J.O.; Lindahl, M.; Janhunen, S.; Kalkkinen, N.; Timmusk, T.; Tuominen, R.K.; Saarma, M. Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo. Nature, 2007, 448(7149), 73-77.
183. Voutilainen, M.H.; Back, S.; Peranen, J.; Lindholm, P.; Raasmaja, A.; Mannisto, P.T.; Saarma, M.; Tuominen, R.K. Chronic infusion of CDNF prevents 6-OHDA-induced deficits in a rat model of Parkinson's disease. Exp. Neurol., 2011, 228(1), 99-108.
184. Baggio, L.L.; Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007, 132, 2131-2157.
185. Garber, A.J. Novel GLP-1 receptor agonists for diabetes. Expert Opin. Investig. Drugs, 2012, 21(1), 45-57.
186. Shyangdan, D.S.; Royle, P.; Clar, C.; Sharma, P.; Waugh, N.; Snaith, A. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst. Rev., 2011(10), CD006423.
187. Craft, S.; Watson, G.S. Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet, 2004, 3, 169-178.
188. Perry, T.; Greig, N.H. The glucagon-like peptides: A double-edged therapeutic sword? Trends Pharmacol. Sci., 2003, 24, 377-383.
189. Perry, T.; Lahiri, D.K.; Chen, D.; Zhou, J.; Shaw, K.T.; Egan, J.M.; Greig, N.H. A novel neurotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells. J. Pharmacol. Exp. Ther., 2002, 300, 958-966.
190. Perry, T.; Haughey, N.J.; Mattson, M.P.; Egan, J.M.; Greig, N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther., 2002, 302, 881-888.
191. Li, Y.; Perry, T.; Kindy, M.S.; Harvey, B.K.; Tweedie, D.; Holloway, H.W.; Powers, K.; Shen, H.; Egan, J.M.; Sambamurti, K.; Brossi, A.; Lahiri, D.K.; Mattson, M.P.; Hoffer, B.J.; Wang, Y.; Greig, N.H. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc. Natl. Acad. Sci. USA, 2009, 106, 1285-1290.
192. Li, Y.; Tweedie, D.; Mattson, M.P.; Holloway, H.W.; Greig, N.H. Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells. J. Neurochem., 2010, 113, 1621-1631.
193. Harkavyi, A.; Abuirmeileh, A.; Lever, R.; Kingsbury, A.E.; Biggs, C.S.; Whitton, P.S. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflammation, 2008, 5, 19.
194. Kim, S.; Moon, M.; Park, S. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. J. Endocrinol., 2009, 202, 431-439.
195. Bertilsson, G.; Patrone, C.; Zachrisson, O.; Andersson, A.; Dannaeus, K.; Heidrich, J, Kortesmaa, J.; Mercer, A.; Nielsen, E.; Rönnholm, H.; Wikström, L. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res., 2008, 86, 326-338.
196. Li, Y.; Duffy, K.; Ottinger, M.A.; Ray, B.; Bailey, J.A.; Holloway, H.W.; Tweedie, D.; Perry, T.; Mattson, M.P.; Kapogiannis, D.; Sambamurti, K.; Lahiri, D.K.; Greig, N.H. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis., 2010, 19, 1205-1219.
197. Perry, T.; Holloway, H.W.; Weerasuriya, A.; Mouton, P.R.; Duffy, K.; Mattison, J.A.; Greig, N.H. Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp. Neurol., 2007, 203, 293-301.
198. Perry, T.; Lahiri, D.K.; Sambamurti, K.; Chen, D.; Mattson, M.P.; Egan, J.M.; Greig, N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res., 2003, 72, 603-612.
199. McClean, P.L.; Parthsarathy, V.; Faivre, E.; Hölscher, C. The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci., 2011, 31(17), 6587-6594.
200. Martin, B.; Golden, E.; Carlson, O.D.; Pistell, P.; Zhou, J.; Kim, W.; Frank, B.P.; Thomas, S.; Chadwick, W.A.; Greig, N.H.; Bates, G.P.; Sathasivam, K.; Bernier, M.; Maudsley, S.; Mattson, M.P.; Egan, J.M. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes, 2009, 58(2), 318-328.
201. Hölscher, C. The role of GLP-1 in neuronal activity and neurodegeneration. Vitam. Horm., 2010, 84, 331-354.
202. Salcedo, I.; Tweedie, D.; Li, Y.; Greig, N.H. Glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative disorders. Br. J. Pharmacol., 2012, Epub ahead of print.
203. Carta, A.R.; Pisanu, A.; Carboni, E. Do PPAR-Gamma Agonists Have a Future in Parkinson's Disease Therapy? Parkinsons Dis., 2011. 2011, 689181.
204. Schintu, N.; Frau, L.; Ibba, M.; Caboni, P.; Garau, A.; Carboni, E.; Carta, A.R. PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. Eur. J. Neurosci., 2009, 29(5), 954-963.
205. Carta, A.R.; Frau, L.; Pisanu, A.; Wardas, J.; Spiga, S.; Carboni, E. Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's diseasemodel. Neuroscience, 2011, 194, 250-261.
206. Germino, F.W. Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review. Clin. Ther., 2011, 33(12), 1868-1882.
207. Cheung, B.M. Behind the rosiglitazone controversy. Expert Rev. Clin. Pharmacol., 2010, 3(6), 723-725.
208. Geldmacher, D.S.; Fritsch, T.; McClendon, M.J.; Landreth, G. A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease. Arch. Neurol., 2011, 68(1), 45-50.
209. Martinez, T.N.; Greenamyre, J.T. Toxin models of mitochondrial dysfunction in Parkinson's disease. Antioxid. Redox Signal., 2011, 16(9), 920-934.
210. Nagatsu, T.; Sawada, M. Cellular and molecular mechanisms of Parkinson's disease: neurotoxins, causative genes, and inflammatory cytokines. Cell. Mol. Neurobiol., 2006, 26, 781-802.
211. Polanski, W.; Reichmann, H.; Gille, G. Stimulation, protection and regeneration of dopaminergic neurons by 9-methyl-α-carboline: a new anti-Parkinson drug? Exp. Rev. Neurother., 2011, 11(6), 845-860.
212. Polanski, W.; Enzensperger, C.; Reichmann, H.; Gille, G. The exceptional properties of 9-methyl-beta-carboline: stimulation, protection and regeneration of dopaminergic neurons coupled with anti-inflammatory effects. J. Neurochem., 2010, 113(6), 1659-1675.
213. Hamann, J.; Rommelspacher, H.; Storch, A.; Reichmann, H.; Gille, G. Neurotoxic mechanisms of 2, 9-dimethyl-beta-carbolinium ion in primary dopaminergic culture. J. Neurochem., 2006, 98, 1185-1199.
214. Matsubara, K.; Kobayashi, S.; Kobayashi, Y.; Yamashita, K.; Koide, H.; Hatta, M.; Iwamoto, K.; Tanaka, O.; Kimura, K. Beta-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology, 1995, 45, 2240-2245.
215. Hamann, J., Wernicke C., Lehmann J., Reichmann H., Rommelspacher H. and Gille G. 9-Methyl-beta-carboline upregulates the appearance of differentiated dopaminergic neurons in primary mesencephalic culture. Neurochem. Int., 2008, 52, 688-700.
216. Wernicke, C.; Hellmann, J.; Zieba, B.; Kuter, K.; Ossowska, K.; Frenzel, M.; Dencher, N.A.; Rommelspacher, H. 9-Methyl-betacarboline has restorative effects in an animal model of Parkinson's disease. Pharmacol. Rep., 2010, 62(1), 35-53.
217. Murata, M. The discovery of an antiparkinsonian drug, zonisamide. Clin. Neurol., 2010, 50(11), 780-782.
218. Yokoyama, H.; Yano, R.; Kuroiwa, H.; Tsukada, T.; Uchida, H.; Kato, H.; Kasahara, J.; Araki, T. Therapeutic effect of a novel antiparkinsonian agent zonisamide against MPTP(1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) neurotoxicity in mice. Metab. BrainDis., 2010, 25(2), 135-143.
219. Choudhury, M.E.; Moritoyo, T.; Kubo, M.; Kyaw, W.T.; Yabe, H.; Nishikawa, N.; Nagai, M.; Matsuda, S.; Nomoto, M. Zonisamideinduced long-lasting recovery of dopaminergic neurons from MPTP-toxicity. Brain Res., 2011, 1384, 170-178.
220. Bourque, M.; Dluzen, D.E.; Di Paolo, T. Neuroprotective actions of sex steroids in Parkinson's disease. Front. Neuroendocrinol., 2009, 30(2), 142-157.
221. Gillies, G.E.; McArthur, S. Estrogen actions in the brain and the basis for differential action in men and women: a case for sexspecific medicines. Pharmacol. Rev., 2010, 62(2), 155-198.
222. Liaw, J.J.; He, J.R.; Hartman, R.D.; Barraclough, C.A. Changes in tyrosine hydroxylase mRNA levels in medullary A1 and A2 neurons and locus coeruleus following castration and estrogen replacement in rats. Brain Res. Mol. Brain Res., 1992, 13, 231-238.
223. Gayrard, V.; Malpaux, B.; Tillet, Y.; Thiery, J.C. Estradiol increases tyrosine hydroxylase activity of the A15 nucleus dopaminergic neurons during long days in the ewe. Biol. Reprod., 1994, 50, 1168-1177.
224. Serova, L.; Rivkin, M.; Nakashima, A.; Sabban, E.L. Estradiol stimulates gene expression of norepinephrine biosynthetic enzymes in rat locus coeruleus. Neuroendocrinology, 2002, 75, 193-200.
225. Ivanova, T.; Beyer, C. Estrogen regulates tyrosine hydroxylase expression in the neonate mouse midbrain. J. Neurobiol., 2003, 54, 638-647.
226. Brann, D.W.; Dhandapani, K.; Wakade, C.; Mahesh, V.; Khan, M.M. Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications. Steroids, 2007, 72, 381-405.
227. Nakashima, A.; Ota, A.; Sabban, E.L. Interactions between Egr1 and AP1 factors in regulation of tyrosine hydroxylase transcription. Brain Res. Mol. Brain Res., 2003, 112, 61-69.
228. Rantham Prabhakara, J.P.; Feist, G.; Thomasson, S.; Thompson, A.; Schommer, E.; Ghribi, O. Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on tyrosine hydroxylase and alpha-synuclein in human neuroblastoma SHSY5Y cells. J. Neurochem., 2008, 107(6), 1722-1729.
229. Marwarha, G.; Rhen, T.; Schommer, T.; Ghribi, O.; The oxysterol 27-hydroxycholesterol regulates α-synuclein and tyrosine hydroxylase expression levels in human neuroblastoma cells through modulation of liver X receptors and estrogen receptors-Relevance to Parkinson's disease. J. Neurochem., 2011, 119(5), 1119-1136.
230. Alerte, T.N.; Akinfolarin, A.A.; Friedrich, E.E.; Mader, S.A.; Hong, C.S.; Perez, R.G. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice. Neurosci. Lett., 2008, 435(1), 24-29.
231. Perez, R.G.; Waymire, J.C.; Lin, E.; Liu, J.J.; Guo, F.; Zigmond, M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci., 2002, 22(8), 3090-3099.
232. Li, Y.H.; Gao, N.; Ye, Y.W.; Li, X.; Yu, S.; Yang, H.; Uéda, K.; Chan, P. Alpha-synuclein functions as a negative regulator for expression of tyrosine hydroxylase. Acta Neurol. Belg., 2011, 111(2), 130-135.
233. Ames, M.; Lerner, P.; Lovenberg, W. Tyrosine hydroxylase activation by protein phosphorylation and end product inhibition. J. Biol. Chem., 1978, 253, 27-31.
234. Birkmayer, J.G.D.; Vrecko, C.; Volc, D.; Birkmayer, W. Nicotinamide adenine dinucleotide(NADH)-a new therapeutic approach to Parkinson's disease. Acta Neurol. Scand., 1993, 87(146), 32-35.
235. Birkmayer, G.J.; Birkmayer, W. Stimulation of endogenous Ldopa biosynthesis--a new principle for the therapy of Parkinson's disease. The clinical effect of nicotinamide adenine dinucleotide(NADH) and nicotinamide adenine dinucleotidephosphate(NADPH). Acta Neurol. Scand. Suppl., 1989, 126, 183-187.
236. Swerdlow, R.H. Is NADH effective in the treatment of Parkinson's disease? Drugs Ageing, 1998, 13(4), 263-268.
237. Nichol, C.A.; Smith, G.K.; Duch, D.S. Biosynthesis and metabolism of tetrahydrobiopterin and molybdopterin. Ann. Rev. Biochem., 1985, 54, 729-764.
238. Schwab, C.; Klegeris, A.; McGeer, P.L. Inflammation in transgenic mouse models of neurodegenerative disorders. Biochim. Biophys. Acta, 2010, 1802(10), 889-902.
239. McGeer, E.G.; McGeer, P.L. The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs., 2007, 21(10), 789-797.
240. Tansey, M.G.; Goldberg, M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis., 2010, 37(3), 510-518.
241. Frankola, K.A.; Greig, N.H.; Luo, W.; Tweedie, D. Targeting TNF- α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol. Disord. Drug Targets, 2011, 10(3), 391-403.
242. Lahiri, D.K.; Chen, D.; Maloney, B.; Holloway, H.W.; Yu, Q.S.; Utsuki, T.; Giordano, T.; Sambamurti, K.; Greig, N.H. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J. Pharmacol. Exp. Ther., 2007, 320(1), 386-396.
243. Shaw, K.T.; Utsuki, T.; Rogers, J.; Yu, Q.S.; Sambamurti K, Brossi A, Ge YW, Lahiri DK, Greig NH. Phenserine regulates translation of beta -amyloid precursor protein mRNA by a putative interleukin-1 responsive element, a target for drug development. Proc. Natl. Acad. Sci. USA, 2001, 98(13), 7605-7610.
244. Friedlich, A.L.; Tanzi, R.E.; Rogers, J.T. The 5'-untranslated region of Parkinson's disease alpha-synuclein messenger RNA contains a predicted iron responsive element. Mol. Psychiatry, 2007, 12(3), 222-223.
245. Olivares, D.; Huang, X.; Branden, L.; Greig, N.H.; Rogers, J.T. Physiological and pathological role of alpha-synuclein in Parkinson's disease through iron mediated oxidative stress; The roleof a putative iron-responsive element. Int. J. Mol. Sci., 2009, 10(3), 1226-1260.
246. Rogers, J.T.; Mikkilineni, S.; Cantuti-Castelvetri, I.; Smith, D.H.; Huang, X.; Bandyopadhyay, S.; Cahill, C.M.; Maccecchini, M.L.; Lahiri, D.K.; Greig, N.H. The alpha-synuclein 5'untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J. Neural. Transm., 2011, 118, 493-507.
247. Mikkilineni, S.; Cantuti-Castelvetri, I.; Cahill, C.; Greig, N.H.; Rogers, J.T. The anti-cholinesterase phenserine and its enantiomer posiphen as 5'untranslated region directed translation blockers of the Parkinson's alpha synuclein expression. Parkinson's Dis., 2012, In press.
248. Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, Kemnitz JW, Johnson JA, Emborg ME. The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J. Neuroinflammation, 2011, 5, 91.
249. Ashburn, T.T.; Thor, K.B. Drug repositioning: identifying and developing new uses for existing drugs. Nat. Rev. Drug Discov., 2004, 3(8), 673-683.
250. Dolgin, E. Nonprofit disease groups earmark grants for drug repositioning. Nat. Med. 2011, 17(9), 1027.
251. Sardana, D.; Zhu, C.; Zhang, M.; Gudivada, R.C.; Yang, L.; Jegga, A.G. Drug repositioning for orphan diseases. Brief Bioinform., 2011, 12(4), 346-56.